Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer

J. Sven D. Mieog, Susan L. Troyan, Merlijn Hutteman, Kevin J. Donohoe, Joost R. Van Der Vorst, Alan Stockdale, Gerrit Jan Liefers, Hak Soo Choi, Summer L. Gibbs-Strauss, Hein Putter, Sylvain Gioux, Peter J.K. Kuppen, Yoshitomo Ashitate, Clemens W.G.M. Löwik, Vincent T.H.B.M. Smit, Rafiou Oketokoun, Long H. Ngo, Cornelis J.H. Van De Velde, John V. Frangioni, Alexander L. Vahrmeijer

Research output: Contribution to journalArticle

169 Scopus citations

Abstract

Background: Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer requires optimized imaging systems and lymphatic tracers. Materials and Methods: A small, portable version of the FLARE imaging system, termed Mini-FLARE, was developed for capturing color video and two semi-independent channels of NIR fluorescence (700 and 800 nm) in real time. Initial optimization of lymphatic tracer dose was performed using 35-kg Yorkshire pigs and a 6-patient pilot clinical trial. More refined optimization was performed in 24 consecutive breast cancer patients. All patients received the standard of care using 99mTechnetium-nanocolloid and patent blue. In addition, 1.6 ml of indocyanine green adsorbed to human serum albumin (ICG:HSA) was injected directly after patent blue at the same location. Patients were allocated to 1 of 8 escalating ICG:HSA concentration groups from 50 to 1000 μM. Results: The Mini-FLARE system was positioned easily in the operating room and could be used up to 13 in. from the patient. Mini-FLARE enabled visualization of lymphatic channels and SLNs in all patients. A total of 35 SLNs (mean = 1.45, range 1-3) were detected: 35 radioactive (100%), 30 blue (86%), and 35 NIR fluorescent (100%). Contrast agent quenching at the injection site and dilution within lymphatic channels were major contributors to signal strength of the SLN. Optimal injection dose of ICG:HSA ranged between 400 and 800 μM. No adverse reactions were observed. Conclusions: We describe the clinical translation of a new NIR fluorescence imaging system and define the optimal ICG:HSA dose range for SLN mapping in breast cancer.

Original languageEnglish (US)
Pages (from-to)2483-2491
Number of pages9
JournalAnnals of surgical oncology
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Mieog, J. S. D., Troyan, S. L., Hutteman, M., Donohoe, K. J., Van Der Vorst, J. R., Stockdale, A., Liefers, G. J., Choi, H. S., Gibbs-Strauss, S. L., Putter, H., Gioux, S., Kuppen, P. J. K., Ashitate, Y., Löwik, C. W. G. M., Smit, V. T. H. B. M., Oketokoun, R., Ngo, L. H., Van De Velde, C. J. H., Frangioni, J. V., & Vahrmeijer, A. L. (2011). Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Annals of surgical oncology, 18(9), 2483-2491. https://doi.org/10.1245/s10434-011-1566-x